| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
32,149 |
29,172 |
$4.45M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
30,952 |
27,601 |
$3.88M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,719 |
7,392 |
$1.19M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,007 |
2,571 |
$871K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,702 |
3,194 |
$660K |
| 80053 |
Comprehensive metabolic panel |
30,909 |
26,768 |
$448K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
3,718 |
3,276 |
$284K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
7,149 |
2,146 |
$198K |
| 70450 |
Computed tomography, head or brain; without contrast material |
759 |
631 |
$132K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,124 |
446 |
$122K |
| J3490 |
Unclassified drugs |
68,561 |
34,941 |
$112K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,301 |
397 |
$80K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
773 |
703 |
$73K |
| 84484 |
|
8,052 |
4,317 |
$70K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,434 |
6,236 |
$56K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
367 |
73 |
$56K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
871 |
793 |
$52K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
724 |
626 |
$47K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
99 |
36 |
$36K |
| 80320 |
|
304 |
261 |
$31K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
44,108 |
37,704 |
$23K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
175 |
143 |
$23K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
22,169 |
19,491 |
$22K |
| 83605 |
|
1,575 |
1,104 |
$15K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
10,711 |
8,909 |
$15K |
| 97161 |
|
215 |
152 |
$12K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
55 |
45 |
$10K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
13,791 |
12,006 |
$9K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
711 |
614 |
$9K |
| 84443 |
Thyroid stimulating hormone (TSH) |
728 |
694 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,100 |
931 |
$7K |
| 71045 |
Radiologic examination, chest; single view |
5,215 |
4,491 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
192 |
116 |
$6K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
924 |
896 |
$6K |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
191 |
176 |
$5K |
| 36415 |
Collection of venous blood by venipuncture |
2,406 |
1,921 |
$5K |
| 87040 |
|
391 |
180 |
$5K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
389 |
171 |
$4K |
| 80061 |
Lipid panel |
466 |
440 |
$4K |
| 81001 |
|
20,735 |
18,314 |
$3K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
10,190 |
8,808 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
309 |
285 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
15 |
14 |
$3K |
| G0378 |
Hospital observation service, per hour |
25 |
12 |
$3K |
| G0432 |
Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening |
153 |
145 |
$2K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
9,126 |
7,094 |
$2K |
| 86780 |
|
193 |
184 |
$1K |
| 84145 |
|
154 |
125 |
$1K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
22 |
12 |
$1K |
| 80076 |
|
338 |
287 |
$942.60 |
| 84703 |
|
6,114 |
5,597 |
$903.28 |
| 97597 |
|
17 |
12 |
$877.31 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
13 |
13 |
$826.51 |
| 85379 |
|
79 |
67 |
$795.55 |
| 85027 |
|
122 |
113 |
$726.27 |
| 71046 |
Radiologic examination, chest; 2 views |
112 |
106 |
$638.16 |
| 86592 |
|
14 |
13 |
$590.50 |
| 83880 |
|
16 |
13 |
$574.96 |
| 83690 |
|
5,509 |
4,928 |
$467.26 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
520 |
108 |
$430.94 |
| 80055 |
|
13 |
13 |
$394.82 |
| J1756 |
Injection, iron sucrose, 1 mg |
88 |
41 |
$318.38 |
| 82728 |
|
40 |
37 |
$312.52 |
| 83550 |
|
39 |
38 |
$189.37 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
9,087 |
7,966 |
$163.90 |
| 86850 |
|
40 |
39 |
$146.80 |
| 83540 |
|
39 |
38 |
$146.59 |
| 81025 |
|
297 |
281 |
$133.16 |
| J7050 |
Infusion, normal saline solution, 250 cc |
10,202 |
7,658 |
$122.57 |
| 36591 |
|
26 |
12 |
$111.44 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
15 |
12 |
$110.77 |
| 83735 |
|
928 |
792 |
$93.28 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
17 |
12 |
$76.22 |
| 86900 |
|
40 |
39 |
$72.41 |
| 87340 |
|
25 |
24 |
$64.94 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,014 |
957 |
$50.82 |
| 82950 |
|
12 |
12 |
$48.61 |
| 86901 |
|
40 |
39 |
$36.70 |
| 86787 |
|
13 |
12 |
$32.22 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,037 |
4,190 |
$31.32 |
| J2704 |
Injection, propofol, 10 mg |
1,163 |
1,003 |
$21.18 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
937 |
782 |
$5.95 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
680 |
591 |
$2.24 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
342 |
318 |
$1.34 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,041 |
903 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
172 |
151 |
$0.00 |
| 86140 |
|
67 |
50 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
947 |
596 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
42 |
40 |
$0.00 |
| A4217 |
Sterile water/saline, 500 ml |
206 |
187 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
223 |
164 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
100 |
90 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
187 |
138 |
$0.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
108 |
99 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
16 |
13 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
53 |
39 |
$0.00 |
| 88304 |
|
80 |
69 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
27 |
24 |
$0.00 |
| 87088 |
|
25 |
24 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
363 |
266 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
148 |
114 |
$0.00 |
| 85610 |
|
279 |
271 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
390 |
257 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
33 |
29 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
14 |
13 |
$0.00 |
| 80306 |
|
19 |
15 |
$0.00 |
| 84100 |
|
14 |
14 |
$0.00 |